期刊文献+

DETECTION OF SERIAL SERUM P-185 LEVEL IN PATIENTS WITH MALIGNANCY USING ELISA

DETECTION OF SERIAL SERUM P-185 LEVEL IN PATIENTS WITH MALIGNANCY USING ELISA
下载PDF
导出
摘要 Objective: To investigate P-185 contents in serum of the normal person and cancer patients and it's the significance on prognosis of diseases. Methods: We used ELISA method to evaluate P-185 levels in 193 normal persons, 133 malignancies and 34 hepatocirrhosises were evaluated using ELISA method. Results: Normal person had lower expression of P-185. However, malignancy and hepatocirrhosis patients had a significantly higher expression level of P-185 than normal (P〈0.05). Conclusion: ELISA method is an easy and reliable way to measure the level of P-185 in serum. Being a cancer marker, P-185 overexpression can be used for early diagnosis and prognosis of cancer patients. Objective: To investigate P-185 contents in serum of the normal person and cancer patients and it's the significance on prognosis of diseases. Methods: We used ELISA method to evaluate P-185 levels in 193 normal persons, 133 malignancies and 34 hepatocirrhosises were evaluated using ELISA method. Results: Normal person had lower expression of P-185. However, malignancy and hepatocirrhosis patients had a significantly higher expression level of P-185 than normal (P〈0.05). Conclusion: ELISA method is an easy and reliable way to measure the level of P-185 in serum. Being a cancer marker, P-185 overexpression can be used for early diagnosis and prognosis of cancer patients.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2006年第3期214-217,共4页 中国癌症研究(英文版)
关键词 ELISA p-185 MALIGNANCY ELISA p-185 Malignancy
  • 相关文献

参考文献15

  • 1Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene [J]. Science 1985; 230:1132-9.
  • 2Ross JS, Fletcher JA. The HER-2/neu oncogene:prognostic factor, predictive factor and target for therapy [J]. Semin Cancer Biol 1999; 9:125-38.
  • 3Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor [J]. Nature 1986;319:230-4.
  • 4Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 [J]. Cell 1986; 45:649-57.
  • 5Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene [J].Science 1987; 235:177-82.
  • 6Schneider PM, Hung MC, Chiocca SM, et al.Differential expression of the c-erbB-2 gene in the human small cell and non-small cell lung cancer [J].Cancer Res 1989; 49:4968-71.
  • 7D'Emilia J, Bulovas K, D'Ercole K, et al. Expresslon of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon [J]. Oncogene1989; 4:1233-9.
  • 8Mitra AB, Murty VV, Pratap M, et al. ERBB-2(HER-2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix [J].Cancer Res 1994; 54:637-9.
  • 9Tsai CM, Chang KT, Perng RP, et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations [J]. J Natl Cancer Inst 1993; 85:897-901.
  • 10Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistan ce to Taxol via mdr- 1-independent mechanisms [J]. Oncogene 1996; 13:1359-65.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部